Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17A | Q9UEE5 | 6/20 | 0.60 |
| ▸ | STK17B | O94768 | 5/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | SYK | P43405 | 2/20 | 0.50 |
| ▸ | ULK1 | O75385 | 1/20 | 0.50 |
| ▸ | IGF1R | P08069 | 3/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | AXL | P30530 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | CDK1 | P06493 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3458921 | 0.85 | CDK1 (0.57) | STK17ASTK17BMAPK1SYKULK1 | |
| SCHEMBL3344858 | 0.85 | MAPK1 (0.57) | STK17ASTK17BMAPK1SYKULK1 | |
| SCHEMBL3375644 | 0.83 | STK17A (0.56) | STK17ASTK17BMAPK1SYKULK1 | |
| SCHEMBL3448855 | 0.83 | STK17A (0.62) | STK17ASTK17BMAPK1AXL | |
| SCHEMBL13310349 | 0.83 | MAPK1 (0.54) | STK17ASTK17BMAPK1SYKULK1 | |
| SCHEMBL656032 | 0.82 | SYK (0.72) | STK17ASTK17BMAPK1SYKULK1 | |
| SCHEMBL3447782 | 0.81 | STK17A (0.52) | STK17ASTK17BMAPK1ULK1CA2 | |
| SCHEMBL3448429 | 0.81 | STK17A (0.60) | STK17ASTK17BMAPK1 | |
| SCHEMBL3450081 | 0.81 | STK17A (0.53) | STK17ASTK17BMAPK1ULK1IGF1R | |
| SCHEMBL3448261 | 0.81 | STK17A (0.59) | STK17ASTK17BMAPK1AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | STK17A 1984/4885STK17B 2457/4885MAPK1 2905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.